Chepstow, South Wales – 29 November 2017 – Creo Medical Group plc (AIM: CREO) is pleased to announce that Speedboat RS2 has been used by a second Gastroenterologist at a second NHS site to treat further patients. This follows the announcement earlier this year with the first patient being treated at St Marks hospital in London.
Initial feedback from the first two cases at this site confirmed the removal of lesions under local anaesthetic with a procedure time of under one hour. The patients were discharged on the same day and are now under routine follow-up and monitoring. We await final histology results.
Craig Gulliford, Chief Executive Officer of Creo Medical, commented:
We are excited by today’s announcement as it provides further validation of our technology. It is incredible that these patients were conscious, talking to the endoscopist and able to watch the procedure live on screen. While we need to collect additional supportive clinical data, we are encouraged by the results we’ve seen to date. We believe that procedures like this have the potential to eliminate the need for subsequent bowel surgery, with the obvious patient benefits aligned with material advantages to the healthcare system in terms of cost and patient safety.
For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.